Answers are grounded in this paper and cite their sources.
Reports drug resistance prevalence and virological outcomes in HIV-1 patients, suggesting a transition to dolutegravir-based therapy.
China’s national antiretroviral therapy program has relied predominantly on non-nucleoside reverse transcriptase inhibitor-based regimens since 2003, creating sustained drug-selective pressure. We integrated 14-year longitudinal treatment outcomes (2010–2023, n = 635) with cross-sectional resistance surveillance (December 2024–July 2025, n = 268) at Huzhou Central Hospital, Zhejiang Province. Integrase strand transfer inhibitor-based regimens achieved 100% virological suppression at 48 weeks versus 87.9% for tenofovir disoproxil fumarate plus lamivudine plus efavirenz and 67–78% for thymidine analogue plus non-nucleoside reverse transcriptase inhibitor regimens ( p < 0.001). Overall surveillance drug resistance mutation prevalence was 22.4%, exceeding the World Health Organization 10% threshold for transmitted drug resistance. Circulating recombinant form 01_AE was absent from treatment-naïve participants (0%) but represented 24.2% of treatment-experienced sequences ( p < 0.001), with significant molecular transmission clustering ( p = 0.002). Prior virological failure (adjusted odds ratio 4.12, p < 0.001), circulating recombinant form 01_AE subtype (adjusted odds ratio 2.67, p = 0.006), and efavirenz-based versus dolutegravir-based regimen (adjusted odds ratio 2.18, p = 0.030) independently predicted resistance among treatment-experienced patients. These findings provide empirical justification for immediate transition to universal dolutegravir-based first-line therapy with baseline genotypic resistance testing.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: